BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.
Risk and Volatility
BioXcel Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Profitability
This table compares BioXcel Therapeutics and NovoCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioXcel Therapeutics | -10,887.38% | N/A | -181.48% |
| NovoCure | -25.66% | -50.82% | -16.48% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioXcel Therapeutics | $640,000.00 | 48.24 | -$69.90 million | ($6.71) | -0.17 |
| NovoCure | $655.35 million | 3.11 | -$136.23 million | ($1.53) | -11.49 |
BioXcel Therapeutics has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for BioXcel Therapeutics and NovoCure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioXcel Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| NovoCure | 1 | 3 | 4 | 0 | 2.38 |
BioXcel Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 864.91%. NovoCure has a consensus price target of $27.29, suggesting a potential upside of 55.21%. Given BioXcel Therapeutics’ higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than NovoCure.
Institutional & Insider Ownership
30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
NovoCure beats BioXcel Therapeutics on 9 of the 14 factors compared between the two stocks.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
